Sanofi and Cheplapharm have agreed a major mature-medicines transaction covering 20 products and three manufacturing sites in France, Hungary and Singapore.

BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions.

The commercial partnership combines 4basebio’s cell-free hpDNA platform with Genezen’s viral vector CDMO capabilities to provide cell and gene therapy developers with an alternative to conventional plasmid DNA manufacturing.

Meiji Seika Pharma group company KM Biologics and Serum Institute of India (SII) are collaborating to transfer technology for the development and manufacture in India of the Japanese encephalitis vaccine currently produced and marketed by KM Biologics in Japan. SII is expected to seek Indian regulatory approval as early as 2027, with the partnership intended to establish local manufacturing and supply of the vaccine for children in India.

The collaborative initiative aims to generate evidence on the consistency of next-generation sequencing (NGS) testing across routine clinical laboratories, supporting future improvements in precision oncology diagnostics.

The payment strengthens Dimerix's balance sheet while advancing its regional partnering strategy for the Phase III kidney disease therapy DMX-200 across Asia.

The agreements give UroGen access to IntraGel's sustained-release drug delivery platform while supporting development of the Phase II-ready cancer therapy TumoCure through an equity investment and future licensing options.

The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

The portfolio collaboration combines Henlius’ biologics development and manufacturing capabilities with Sandoz’s ex-China commercial infrastructure, initially covering three biosimilars and an option on a recombinant human hyaluronidase programme.

The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets.

The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.

The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.

The research collaboration combines Mediar’s fibrosis biology and antibody discovery capabilities with Ono’s drug development expertise to identify new treatments targeting fibro-inflammatory disease mechanisms.

The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.

The collaboration combines Biocytogen’s fully human antibody discovery platform with Whitehawk’s ADC expertise to develop novel cancer therapies with enhanced targeting potential.

The collaboration will evaluate Vivani’s implantable semaglutide technology as Novo Nordisk looks to expand treatment options beyond once-weekly injections.

The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.

Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.